Generation of high rapamycin producing strain via rational metabolic pathway-based mutagenesis and further titer improvement with fed-batch bioprocess optimization

Biotechnology and Bioengineering

Volumn 107, Issue 3, 2010, Pages 506-515

  Zhu, Xiangcheng ^a   Zhang, Wei ^a,b   Chen, Xiyang ^a   Wu, Hu ^b   Duan, Yanwen ^c   Xu, Zhinan ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b Huadong Medicine Co Ltd   (China)

^c Hunan Engineering Research Center of Combinatorial Biosynthesis and Natural Product Drug Discovery   (China)

Author keywords

Fed batch; Rapamycin; Rational strain improvement; S. hygroscopicus; Scale up fermentation

Indexed keywords

FED BATCHES; RAPAMYCIN; RATIONAL STRAIN IMPROVEMENT; S. HYGROSCOPICUS; SCALE-UP; STRAIN IMPROVEMENT;

AMINO ACIDS; ANTIBIOTICS; BIOCHEMISTRY; CARBOXYLIC ACIDS; DRIERS (MATERIALS); FERMENTERS; GLUCOSE; INDUSTRY; METABOLISM; MUTAGENESIS; OPTIMIZATION; PILOT PLANTS;

FERMENTATION;

GLUCOSE; LYSINE; PHENYLALANINE; RAPAMYCIN; SHIKIMIC ACID; TRYPTOPHAN;

ARTICLE; AUXOTROPHY; BACTERIAL STRAIN; BIOPROCESS; BIOREACTOR; BIOSYNTHESIS; CLINICAL EVALUATION; FED BATCH CULTURE; FERMENTATION; FERMENTATION OPTIMIZATION; INDUSTRIAL PRODUCTION; INDUSTRIALIZATION; METABOLISM; MUTAGENESIS; NONHUMAN; PH; PROCESS OPTIMIZATION; SCREENING; STREPTOMYCES HYGROSCOPICUS; ULTRAVIOLET RADIATION; CARBON SOURCE; DRUG MANUFACTURE; FED BATCH REACTOR; REACTOR OPTIMIZATION;

FERMENTATION; GLUCOSE; LYSINE; METABOLIC NETWORKS AND PATHWAYS; MUTAGENESIS; PHENYLALANINE; SHIKIMIC ACID; SIROLIMUS; STREPTOMYCES; TRYPTOPHAN; ULTRAVIOLET RAYS;

STREPTOMYCES HYGROSCOPICUS;

EID: 84867220160     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.22819     Document Type: Article

References (32)

1. Chen Y, Krol J, Sterkin V, Fan W, Yan X, Huang W, Cino J, Julien C. 1999. New process control strategy used in a rapamycin fermentation. Process Biochem 34:383-389.
2. Chen Y, Krol J, Huang W, Cino J, Vyas R, Mirro R, Vaillancourt B. 2008. DCO2 on-line measurement used in rapamycin fed-batch fermentation process. Process Biochem 43:351-355.
3. Chen X, Wei P, Fan L, Yang D, Zhu X, Shen W, Xu Z, Cen P. 2009. Generation of high-yield rapamycin-producing strains through protoplasts-related techniques. Appl Microbiol Biotechnol 83(3):507-512.
4. Dumont FJ, Su Q. 1996. Mechanism of action of the immunosuppressant rapamycin. Life Sci 58(5):373-395.
5. Foroncewicz B, Mucha K, Paczek L, Chmura A, Rowinski W. 2005. Efficacy of rapamycin in patient with juvenile rheumatoid arthritis. Transpl Int 18(3):366-368.
6. Gatto GJ, Jr., Boyne MT II, Kelleher NL, Walsh CT. 2006. Biosynthesis of pipecolic acid by RapL, a lysine cyclodeaminase encoded in the rapamycin gene cluster. J Am Chem Soc 128(11):3838-3847.
7. Goss RJ, Lanceron SE, Wise NJ, Moss SJ. 2006. Generating rapamycin analogues by directed biosynthesis: Starter acid substrate specificity of mono-substituted cyclohexane carboxylic acids. Org Biomol Chem 4(22):4071-4073.
8. Graziani EI. 2009. Recent advances in the chemistry, biosynthesis and pharmacology of rapamycin analogs. Nat Prod Rep 26(5):602-609.
9. Gregory MA, Hong H, Lill RE, Gaisser S, Petkovic H, Low L, Sheehan LS, Carletti I, Ready SJ, Ward MJ, Kaja AL, Weston AJ, Challis IR, Leadlay PF, Martin CJ, Wilkinson B, Sheridan RM. 2006. Rapamycin biosynthesis: Elucidation of gene product function. Org Biomol Chem 4(19):3565-3568.
10. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M, Javors MA, Fernandez E, Miller RA. 2009. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460(7253):392-395.
11. Huang S, Houghton PJ. 2001. Resistance to rapamycin: A novel anticancer drug. Cancer Metastasis Rev 20(1-2):69-78.
12. Kahan BD. 1998. Emerging strategies for the clinical application of rapamycin. Clin Biochem 31(5):341-344.
13. Kahan BD, Camardo JS. 2001. Rapamycin: Clinical results and future opportunities. Transplantation 72(7):1181-1193.
14. Khaw LE, Bohm GA, Metcalfe S, Staunton J, Leadlay PF. 1998. Mutational biosynthesis of novel rapamycins by a strain of Streptomyces hygroscopicus NRRL 5491 disrupted in rapL, encoding a putative lysine cyclodeaminase. J Bacteriol 180(4):809-814.
15. Kim SH, Zukowski K, Novak RF. 2009. Rapamycin effects on mTOR signaling in benign, premalignant and malignant human breast epithelial cells. Anticancer Res 29(4):1143-1150.
16. Kobayashi S, Kishimoto T, Kamata S, Otsuka M, Miyazaki M, Ishikura H. 2007. Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci 98(5):726-733.
17. Kojima I, Cheng YR, Mohan V, Demain AL. 1995. Carbon source nutrition of rapamycin biosynthesis in Streptomyces hygroscopicus. J Ind Microbiol 14(6):436-439.
18. Lee MS, Kojima I, Demain AL. 1997. Effect of nitrogen source on biosynthesis of rapamycin by Streptomyces hygroscopicus. J Ind Microbiol Biotechnol 19(2):83-86.
19. Lowden PA, Bohm GA, Metcalfe S, Staunton J, Leadlay PF. 2004. New rapamycin derivatives by precursor-directed biosynthesis. Chembiochem 5(4):535-538.
20. Molnar I, Aparicio JF, Haydock SF, Khaw LE, Schwecke T, Konig A, Staunton J, Leadlay PF. 1996. Organisation of the biosynthetic gene cluster for rapamycin in Streptomyces hygroscopicus: Analysis of genes flanking the polyketide synthase. Gene 169(1):1-7.
21. Nicoletti F, Lapenta C, Donati S, Spada M, Ranazzi A, Cacopardo B, Mangano K, Belardelli F, Perno C, Aquaro S. 2009. Inhibition of human immunodeficiency virus (HIV-1) infection in human peripheral blood leucocytes-SCID reconstituted mice by rapamycin. Clin Exp Immunol 155(1):28-34.
22. Paiva NL, Demain AL, Roberts MF. 1991. Incorporation of acetate, propionate, and methionine into rapamycin by Streptomyces hygroscopicus. J Nat Prod 54(1):167-177.
23. Paiva NL, Demain AL, Roberts MF. 1993a. The immediate precursor of the nitrogen-containing ring of rapamycin is free pipecolic acid. Enzyme Microb Technol 15:581-585.
24. Paiva NL, Roberts MF, Demain AL. 1993b. The cyclohexane moiety of rapamycin is derived from shikimic acid in Streptomyces hygroscopicus. J Ind Microbiol 12:423-428.
25. Perera SA, Li D, Shimamura T, Raso MG, Ji H, Chen L, Borgman CL, Zaghlul S, Brandstetter KA, Kubo S, Takahashi M, Chirieac LR, Padera RF, Bronson RT, Shapiro GI, Greulich H, Meyerson M, Guertler U, Chesa PG, Solca F, Wistuba II, Wong KK. 2009. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci USA 106(2):474-479.
26. Ruan X, Stassi D, Lax SA, Katz L. 1997. A second type-I PKS gene cluster isolated from Streptomyces hygroscopicus ATCC 29253, a rapamycinproducing strain. Gene 203(1):1-9.
27. Schwecke T, Aparicio JF, Molnar I, Konig A, Khaw LE, Haydock SF, Oliynyk M, Caffrey P, Cortes J, Lester JB, Bohm GA, Staunton J, Leadlay PF. 1995. The biosynthetic gene cluster for the polyketide immunosuppressant rapamycin. Proc Natl Acad Sci USA 92(17):7839-7843.
28. Shi Y, August DA. 2008. A new trick for an old drug: mTOR inhibitor rapamycin augments the effect of fluorouracil on hepatocellular carcinoma by inducing cell senescence. Cancer Biol Ther 7(3):397-398.
29. Staunton J, Wilkinson B. 1997. Biosynthesis of erythromycin and rapamycin. Chem Rev 97(7):2611-2630.
30. Tain LS, Mortiboys H, Tao RN, Ziviani E, Bandmann O, Whitworth AJ. 2009. Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat Neurosci
31. Xu ZN, Shen WH, Chen XY, Lin JP, Cen PL. 2005. A high-throughput method for screening of rapamycin-producing strains of Streptomyces hygroscopicus by cultivation in 96-well microtiter plates. Biotechnol Lett 27(15):1135-1140.
32. Zou CY, Smith KD, Zhu QS, Liu J, McCutcheon IE, Slopis JM, Meric-Bernstam F, Peng Z, Bornmann WG, Mills GB, Lazar AJ, Pollock RE, Lev D. 2009. Dual targeting of AKT and mammalian target of rapamycin: A potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol Cancer Ther 8(5):1157-1168.